公开(公告)号：GEP20196942B

公开(公告)日：2019-02-11

申请号：GEAP2015014401

申请日：2015-06-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: C07D217/14 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/4741 ,  A61P11/06 ,  A61P17/06 ,  A61P19/02 ,  A61P43/00 ,  C07D471/04 ,  C07D491/14

Abstract: An invention relates to heterocyclic compounds of RORγt inhibitive activity, of formula (I), or salt thereof; and their usage at psoriasis, crown desease, multiple sclerosis, etc. treatment, as well.

公开(公告)号：GEP20186909B

公开(公告)日：2018-10-25

申请号：GEAP2015014272

申请日：2015-02-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: A61P25/18 ,  A61K31/428 ,  C07D263/58 ,  C07D277/82 ,  C07D401/04

Abstract: Compound of formula (I), (I) wherein values of R1, R2, R3, Ra, Rb, L, X substitudes are provided in the claims or pharmaceutically acceptable salt thereof, pharma¬ceutical compositions containing them, and their usage at the therapy. Table: 1

公开(公告)号：GEP20186893B

公开(公告)日：2018-09-10

申请号：GEAP2015014266

申请日：2015-02-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: A61P25/00 ,  A61K31/497 ,  A61K31/5377 ,  C07D241/26 ,  C07D241/28 ,  C07D401/04

Abstract: Compound of formula I, I pharmaceutical compositions on basis thereof and their usage at the treatment of conditions related to GPR6. Table: 1

公开(公告)号：GEP20197050B

公开(公告)日：2019-12-10

申请号：GEAP2015014545

申请日：2015-12-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: C07D471/04

Abstract: An invention relates to crystalline form of 6-(lR,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-me-thyl-1H-pyrazol-4-yl)-lH-pyrrolo[3,4-c]pyridine-3 (2H)-one citrate, which is inhibitor of spleen tyrosine kinase (SYK); and usage of this compound for cancer treatment, as well.

公开(公告)号：GEP20196970B

公开(公告)日：2019-04-25

申请号：GEAP2015014277

申请日：2015-02-23

Applicant: TAKEDA GMBH ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA GMBH ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: C07K14/81 ,  A61K38/17

Abstract: Present invention provides UTI fusion proteins, DNA sequences for producing thereof, and pharma¬ceutical compositions and methods of their usage.

公开(公告)号：GEP20196961B

公开(公告)日：2019-03-25

申请号：GEAP2015014515

申请日：2015-11-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: C07D253/08 ,  A61K31/53

Abstract: An invention relates to oxobenzo [d] [1,2,3] triazine acetamides of formula (II), containing pharmaceutical compositions thereof, and their usage for the treatment of diseases related to GPR139.

公开(公告)号：GEP20196984B

公开(公告)日：2019-06-25

申请号：GEAP2015014284

申请日：2015-03-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: A61K31/501 ,  A61P25/14 ,  A61P25/00

Abstract: An invention relates to hydroxypyridazine derivatives of formula (I), (I) pharmaceutically acceptable salts thereof, their usage for the prevention or treatment of an ataxic disorder.

公开(公告)号：GEP20186910B

公开(公告)日：2018-10-25

申请号：GEAP2015014273

申请日：2015-02-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： TAKEDA PHARMACEUTICAL COMPANY LIMITED

IPC: A61P25/18 ,  A61K31/44 ,  A61K31/506 ,  C07D213/74 ,  C07D231/12 ,  C07D239/42 ,  C07D249/06 ,  C07D271/07

Abstract: Compound of formula (I), (I) wherein values of R1, R2, R3, Ra, Rb, L, X substitudes are provided in the claims or pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and their usage at the therapy. Table: 1